The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer.
about
Indications for staging laparoscopy in pancreatic cancerPrognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy.Clinical significance of serum p53 antigen in patients with pancreatic carcinomasAdjuvant chemoradiation for pancreatic cancer: what does the evidence tell us?Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients.Diagnostic and prognostic tumor markers in the gastrointestinal tract.Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer.Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010.53BP1 expression is a modifier of the prognostic value of lymph node ratio and CA 19-9 in pancreatic adenocarcinoma.Evaluation of survival in patients after pancreatic head resection for ductal adenocarcinoma.Biological variation and reference change values of CA 19-9, CEA, AFP in serum of healthy individuals.Huachansu injection inhibits metastasis of pancreatic cancer in mice model of human tumor xenograft.Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinomaValue of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer.Predictors of the patency of self-expandable metallic stents in malignant gastroduodenal obstruction.Risk Factors Associated with Loco-Regional Failure after Surgical Resection in Patients with Resectable Pancreatic CancerAdvances in biomarker research for pancreatic cancer.Systemic Inflammatory Response and Elevated Tumour Markers Predict Worse Survival in Resectable Pancreatic Ductal AdenocarcinomaAdenocarcinoma arising from jejunal ectopic pancreas mimicking peritoneal metastasis from colon cancer: a case report and literature review.Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas?Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer.Strategies for discovering novel pancreatic cancer biomarkers.Lymph node ratio and preoperative CA 19-9 levels predict overall survival and recurrence-free survival in patients with resected pancreatic adenocarcinoma.Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancerPrognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabineMolecular markers of pancreatic cancer: development and clinical relevance.Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer.Plasma and tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer.Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review.Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemoradiation.Pancreatic carcinoma in perspective. A continuing challenge.The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma.Efficacy of percutaneous transhepatic cholangiodrainage (PTCD) in patients with unresectable pancreatic cancer.Noninvasive assessment of tumor vascularity by contrast-enhanced ultrasonography and the prognosis of patients with nonresectable pancreatic carcinoma.Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio.Clinical usefulness of CA-19-9 in pancreatic carcinoma.Combination of tumour markers CEA and CA19-9 improves the prognostic prediction in patients with pancreatic cancer.CA 19–9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer
P2860
Q26771578-456D51A0-EE38-467D-B83E-A180C2F323BCQ31911615-99694359-2D03-4008-9A7A-037F8B8819A3Q33618106-B5F50EDB-560F-4FBB-8752-45B1A1CFB289Q33820788-3997527D-F76E-4131-B3D1-2FA35BD00EA4Q34234101-991F731B-1AD1-4A6B-B070-EB1DA241E021Q34277292-F8E967E0-39CD-4023-B7FC-CF432E5756CAQ34610862-36B8580B-E6D4-4A12-BAEB-DCA11CF29331Q34618231-44AD3FED-AF92-43FD-8C71-D5FC63F7CD8FQ34635042-3DED3ABD-493E-4F8F-9E36-F8D953329342Q34636501-3380DC85-9E34-467A-8D36-95CC28EBD1FFQ34680864-1FA8AAB3-40AA-4500-9342-3E3FF6EE78F2Q34699940-979C91F1-EF43-464B-A883-F5C4A9F40248Q35059946-9EA0C22A-4071-458D-8640-D0C5326BA278Q35089310-739963AD-9838-4A80-8347-50D4ACB8B704Q35517344-2E937191-AD72-4AEE-BB9D-D88613CF23A6Q35942425-EEE70EA2-4BDB-4C03-93DC-7D48F866AD66Q36058855-091DBFF2-3522-4D3A-9CDE-41284D547686Q36126609-D7DF89E2-33AE-49C5-B7A7-EF91291E134AQ36134440-3372FBE1-52D9-465B-802F-398246E0A3C9Q36289646-E2A454E9-8B81-47D4-865C-B6EDC2FDF41DQ36294910-45E67EA4-F34E-42C0-B3DC-632BDD73372EQ36561493-64E1AB20-7393-47A4-B2C0-3698EEB4AD16Q36579311-A65D81D2-0DB4-48D9-B638-164901330BC2Q36637079-43D87202-4E3A-4F89-A173-379F0C10DFA0Q36641445-541CC8B7-FD1F-4CD6-B0DD-B22157F789E2Q36671332-EDB272F1-C939-4DC2-A38B-C91D107DC3EEQ37081461-58143F9C-65C6-4F7D-9EBF-C445CA8BDFA5Q37339612-99F55D80-EDB5-4EA2-9D23-6CBCC613DDB5Q37687708-4F3FAAB7-1937-4B28-8178-0637DEAEE122Q38018315-B2B7303D-C46A-4F00-9624-B2EF80EA1B41Q39740700-4C8E0900-498B-42EF-9A62-DCDFA71533F5Q41016168-229065D8-7FB2-44B7-B208-4443E265FBB1Q42238114-4C2383BA-AAD9-4E29-AB96-32B437D22640Q43022689-29DDA446-4AB7-4446-893A-1DED133115D2Q44847900-B37429B4-4758-4909-948A-A21148D1D39DQ45239466-F014A388-A82D-4C12-8F3E-1B853E7E7A89Q45241867-78B95543-0C4A-4060-BEB7-5B5B0EC0CCA2Q47810833-A06976E1-B5FF-4EDF-8AC4-9E3C0F2D611FQ50579768-79D73217-3C4D-4341-B134-334CB26669B7Q58230752-459ACCEC-7CC9-4A70-8B3E-5A80FEC5023C
P2860
The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
The prognostic value of preope ...... tients with pancreatic cancer.
@en
type
label
The prognostic value of preope ...... tients with pancreatic cancer.
@en
prefLabel
The prognostic value of preope ...... tients with pancreatic cancer.
@en
P2093
P2860
P356
P1476
The prognostic value of preope ...... atients with pancreatic cancer
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1994.93
P407
P50
P577
1994-03-01T00:00:00Z